TT-20

About Tellus Therapeutics

Tellus Therapeutics is a private, early-stage biotech founded with a mission to address critical, unmet medical needs in neonatal care, specifically brain and gut injuries in premature infants. The company's lead candidate, TT-20, is a pioneering myelination therapy targeting neonatal white matter injury, representing a novel regenerative medicine approach. Tellus is building a platform based on breakthrough discoveries in neonatology and is actively engaged in the North Carolina life sciences ecosystem, presenting at investor events like Triangle Venture Day. The company's strategy is to start where the need is greatest—the NICU—and expand its technology to broader neuro-regenerative applications.

Therapeutic Areas